Investigating Associations Between Acute Abuse Liability Outcomes and Switching Behavior
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
FDA OFFICE OF ACQ GRANT SVCS
Contract Value
Not provided
Codes & Classification
Solicitation Number
75F40126R00031
NAICS
541380 - Testing Laboratories and Services
Classification Code
Q301
Additional Details
Documents2
The Food and Drug Administration (FDA), operating under the Department of Health and Human Services, has issued a Combined Synopsis/Solicitation for services related to the investigation of associations between acute abuse liability outcomes and switching behavior. This procurement seeks to engage qualified entities capable of providing specialized testing laboratory services, as classified under NAICS code 541380 (Testing Laboratories and Services), to support research efforts in this critical area.
The primary objective of this contract is to conduct rigorous scientific investigations that elucidate the relationship between acute abuse liability—essentially, the potential for substances to be misused or abused in the short term—and patterns of switching behavior among users. The intended outcome is to generate robust data and insights that can inform regulatory decisions, public health policies, and future research initiatives related to substance use and abuse.
The scope of work will require the contractor to design and implement laboratory-based studies, collect and analyze relevant data, and provide comprehensive reports detailing findings and their implications. Key deliverables are expected to include detailed study protocols, validated data sets, interim and final analytical reports, and recommendations based on the observed associations between acute abuse liability and switching behavior. Contractors must demonstrate expertise in advanced laboratory testing methodologies, data analysis, and the interpretation of behavioral outcomes in the context of substance use.
This opportunity is not set aside for any specific small business or socioeconomic category, and is open to all qualified vendors. The place of performance is Silver Spring, Maryland, where the FDA’s Office of Acquisition and Grant Services is located. The procurement is managed by the FDA Office of Acquisition and Grant Services, with Janice Heard serving as the primary point of contact ([email protected], 215-717-3093).
The solicitation is currently active, with a response deadline of July 6, 2026. Interested parties are encouraged to review the full solicitation and associated attachments, which provide comprehensive details on requirements, submission instructions, and evaluation criteria. The opportunity is posted on SAM.gov under Opportunity ID d7d33bd8edd54eb594758fe37a82ec9d.
Contractors considering this opportunity should have a proven track record in laboratory-based research, particularly in the assessment of abuse liability and behavioral outcomes, and the capacity to deliver high-quality, scientifically rigorous results within the specified timeframe. This procurement represents a significant opportunity to contribute to the FDA’s mission of protecting public health through evidence-based regulation and oversight of substances with abuse potential.